Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/51636
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Evaluation of a novel calpain inhibitor as a treatment for cataract
Author: Lee, H.
Morton, J.
Robertson, L.
McDermott, J.
Bickerstaffe, R.
Abell, A.
Jones, M.
Mehrtens, J.
Coxon, J.
Citation: Clinical and Experimental Ophthalmology, 2008; 36(9):852-860
Publisher: Blackwell Publishing Asia
Issue Date: 2008
ISSN: 1442-6404
1442-9071
Statement of
Responsibility: 
Hannah YY Lee, James D Morton, Lucinda JG Robertson, Joshua D McDermott, Roy Bickerstaffe, Andrew D Abell, Matthew A Jones, Janna M Mehrtens and James M Coxon
Abstract: Purpose: The aim of this study is to evaluate the therapeutic potential of a newly synthesized calpain inhibitor, CAT0059, using a naturally occurring in vivo sheep cataract model. Methods: The selectivity of CAT0059 was investigated by an in vitro protease assay. The efficacy of CAT0059 in preventing proteolysis of lens cytoskeletal proteins by calpain 2 was investigated using a lens-based cell-free method. The cytotoxicity and stability of CAT0059 in physiological conditions were examined using cultured sheep lenses. Protein binding of CAT0059 by ocular proteins was assessed and quantified by a modified high-performance liquid chromatography assay. CAT0059 was formulated in an eye drop solution and as an eye ointment. These were applied in vivo daily to one eye of the cataract lambs, over a 67- and 97-day trial period, respectively. The progression of cataracts in the treated and untreated eyes was assessed by an independent veterinary ophthalmologist using a slit-lamp microscope. Results: In vitro assays revealed that CAT0059 was selective for cysteine proteases and also protected lens cytoskeletal proteins from degradation. CAT0059 was stable in physiological conditions and non-toxic to the lens. Only 15% of CAT0059 is bound to proteins in the aqueous humour but >90% bound to lens homogenate. The 67-day CAT0059 eye drop treatment was not effective in slowing the rate of cataract development. However, application of CAT0059 in an eye ointment initially slowed cataract development compared with the untreated eye. This effect was temporary. Conclusions: In vitro assays confirmed CAT0059 to be a potent calpain inhibitor. The two in vivo trials addressed the ability of CAT0059 to reach the lens and established its limitations as a therapeutic molecule for cataract treatment.
Keywords: calpain inhibitor; CAT0059; cytoskeleton; inherited cataract
Rights: Journal compilation © 2008 Royal Australian and New Zealand College of Ophthalmologists
RMID: 0020084481
DOI: 10.1111/j.1442-9071.2009.01925.x
Appears in Collections:Chemistry and Physics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.